SOUTH EASTON, Mass., Oct. 8 PressureBioSciences, Inc. (Nasdaq: PBIO) ("PBI") today provided an update on variouscorporate activities, including the presentation of favorable data generatedby scientists at Amgen, Inc. on the Company's pressure cycling technology("PCT"), the scheduled presentation by Dr. Paul Pevsner of the NYU School ofMedicine on the use of PCT in identifying potential protein biomarkers incolon cancer samples, and guidance relative to forecasted Q32008 and FY2008sales of the Company's Barocycler instruments.
1) Amgen Presentation: data were presented by scientists from Amgen at the35th meeting of the Federation of Analytical Chemistry and SpectroscopySocieties (FACSS) comparing PCT to their standard overnight procedure and thepopular CEM, Inc. microwave-assisted technique for the digestion of atherapeutic monoclonal antibody. Amgen scientists reported that, "Pressurecycling was shown to be most effective at achieving complete digestion in ashort time, without unintended perturbation of the molecule. Microwavedigestion did not achieve complete digestion and induced oxidation ofmethionine residues." The authors concluded that, "PCT represents an increasein throughput and efficiency of at least 20-fold over the current conditions... pressure cycling provided the most effective method for digestingmonoclonal antibodies."
2) Dr. Paul Pevsner Presentation: Dr. Pevsner, Associate Professor ofPharmacology at the NYU School of Medicine, is scheduled to speak at the"Discovery2Diagnostics" Conference (San Diego, CA) on Monday, October 20th.Dr. Pevsner's talk, entitled "MALDI Imaging and Mass SpectrometryIdentification of Colorectal Cancer Biomarkers", will include a discussion onthe advantages of PCT versus other sample preparation methods available today.Dr. Pevsner is also expected to present data on the discovery of severalproteins that he and his colleagues have found in colon cancer samples usingPCT that have not been previously found in similar samples using other samplepreparation techniques.
3) Guidance on Barocycler Sales: on August 14th, the Company announcedthat it expected to install at least fourteen (14) PCT Sample PreparationSystems during Q32008. The Company is pleased to announce that it hasinstalled 17 PCT Systems, as compared to 7 in the second quarter of 2008.Furthermore, the Company expects to meet or exceed its previously announcedfull year guidance of 40 installations.
Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc.,commented: "The continued publications and presentations from early adoptersof PCT is helping us tremendously in our commercialization efforts. Weattribute a significant portion of our recent commercial success totestimonials like the ones highlighted above, that herald the merits ofpressure cycling technology in various applications of life sciences, as wellas the advantages of PCT over other sample preparation methods availabletoday. We would like to congratulate our customers and collaborators fortheir important research studies and for their continued support of PCT."
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) is a publicly-traded company focused onthe development and commercialization of a novel, enabling technology calledpressure cycling technology (PCT). PCT uses cycles of hydrostatic pressurebetween ambient and ultra-high levels (up to 35,000 psi and greater) tocontrol bio-molecular interactions. PBI currently holds 13 US and 6 foreignpatents covering multiple applications of PCT in the life sciences field,including in such areas as genomic and proteomic sample preparation, pathogeninactivation, the control of chemical reactions, immunodiagnostics, andprotein purification.
Forward Looking Statements
Statements contained in this press release regarding the Company'sintentions, hopes, beliefs, expectations, or predictions of the future are"forward-looking" statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995. Such forward looking statements includestatements regarding data presented at the FACSS Meeting by scientists atAmgen; the expected presentation by Dr. Paul Pevsner at the upcomingDiscovery2Diagnostics Conference; and expected installations of Barocyclerinstruments during Q32008 and expected installations during FY2008. Thesestatements are based upon the Company's current expectations, forecasts, andassumptions that are subject to risks, uncertainties, and other factors thatcould cause actual outcomes and results to differ materially from thoseindicated by these forward-looking statements. These risks, uncertainties,and other factors include, but are not limited to: the possibility that otherscientists will be unable to reproduce the findings reported by scientists atAmgen that indicate that PCT provides a most effective method for digestingmonoclonal antibodies; due to scientific and medical challenges, thepossibility that the data generated by Dr. Pevsner and his colleagues to bepresented at the October 2008 Discovery2Diagnostics Conference, may not bereproduced by other researchers in the future; that due to competitiveproducts, services, and technological advances, PCT may not be the preferredmethod of sample preparation by other scientists and laboratories; thepossibility that due to unforeseen issues, the Company may not installseventeen (17) PCT Systems in Q32008 and it may not meet or exceed (40)installations in FY2008; and the other risks and uncertainties discussed underthe heading "Risk Factors" in the Company's Annual Report on Form 10-K for theyear ended December 31, 2007, and other reports filed by the Company from timeto time with the SEC. The Company undertakes no obligation to update any ofthe information included in this release, except as otherwise required by law.Visit us at our website http://www.pressurebiosciences.com . Investor Contacts: Richard T. Schumacher, President & CEO Pressure BioSciences, Inc. Edward H. Myles, Sr. Vice President of Finance & CFO (508) 230-1828 (T)
SOURCE Pressure BioSciences, Inc.